WO2011090954A2 - Engineered opsonin for pathogen detection and treatment - Google Patents

Engineered opsonin for pathogen detection and treatment Download PDF

Info

Publication number
WO2011090954A2
WO2011090954A2 PCT/US2011/021603 US2011021603W WO2011090954A2 WO 2011090954 A2 WO2011090954 A2 WO 2011090954A2 US 2011021603 W US2011021603 W US 2011021603W WO 2011090954 A2 WO2011090954 A2 WO 2011090954A2
Authority
WO
WIPO (PCT)
Prior art keywords
opsonin
recombinant
binding
domain
mbl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/021603
Other languages
English (en)
French (fr)
Other versions
WO2011090954A3 (en
Inventor
Michael Super
Jeffrey Charles Way
Donald E. Ingber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IN6589DEN2012 priority Critical patent/IN2012DN06589A/en
Priority to CN201180014755.1A priority patent/CN102947341B/zh
Priority to ES11735056.1T priority patent/ES2678143T3/es
Priority to JP2012550067A priority patent/JP5959440B2/ja
Priority to US13/574,191 priority patent/US9150631B2/en
Priority to EP11735056.1A priority patent/EP2526119B1/en
Priority to DK11735056.1T priority patent/DK2526119T3/en
Application filed by Harvard University filed Critical Harvard University
Priority to CA2787376A priority patent/CA2787376A1/en
Priority to SG2012052965A priority patent/SG182577A1/en
Priority to AU2011207626A priority patent/AU2011207626B2/en
Publication of WO2011090954A2 publication Critical patent/WO2011090954A2/en
Publication of WO2011090954A3 publication Critical patent/WO2011090954A3/en
Anticipated expiration legal-status Critical
Priority to US14/831,480 priority patent/US20160200785A1/en
Priority to US15/839,352 priority patent/US10538562B2/en
Priority to US16/702,724 priority patent/US11059873B2/en
Priority to US16/892,575 priority patent/US11203623B2/en
Priority to US16/892,577 priority patent/US11059874B2/en
Priority to US17/522,115 priority patent/US20220056089A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4726—Lectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56961—Plant cells or fungi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/37—Assays involving biological materials from specific organisms or of a specific nature from fungi
    • G01N2333/39—Assays involving biological materials from specific organisms or of a specific nature from fungi from yeasts
    • G01N2333/40—Assays involving biological materials from specific organisms or of a specific nature from fungi from yeasts from Candida
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/72—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating magnetic variables
    • G01N27/74—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating magnetic variables of fluids
    • G01N27/745—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating magnetic variables of fluids for detecting magnetic beads used in biochemical assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • An embodiment of the invention provides for a method of collecting an opsonin- binding microorganism from a fluid comprising contacting the fluid with a recombinant opsonin conjugated to a solid surface; wherein the recombinant opsonin consists of a carbohydrate recognition domain of an opsonin, a solid substrate binding domain, and a flexible peptide domain that links the recognition domain to the solid surface binding domain; allowing the opsonin-binding microorganism to bind to said recombinant opsonin-solid surface conjugate; and separating said fluid from said microorganism-bound recombinant opsonin-solid surface conjugate.
  • the fluid may be a biological fluid, such as blood, obtained from a subject. The fluid may then be returned to the subject.
  • MBL is a key component in opsonization of microbial pathogens and in the activation of complement (via the lectin pathway) and coagulation.
  • Opsonization is the binding of proteins to target cells and the targeting these cells for uptake and destruction by phagocytic cells, such as macrophages and neutrophils. This opsonization appears to be mediated by the small, cysteine -rich N-terminal domain of MBL as well as C3b deposited on the target cell surface by MBL-mediated lectin complement pathway activation.
  • MASP-1 Mannan-binding lectin Associated Serine Protease
  • M. tuberculosis engage macrophage mannose receptor (MMR) during the phagocytic process. This directs M. tuberculosis to its initial phagosomal niche and inhibits phagosome-lysosome (P-L) fusion, thereby enhancing survival in human macrophages. Interestingly, inhibition of P-L fusion did not occur with entry via Fey receptors.
  • uptake by Fc recetor endocytosis routes the bacterium, e.g., M. tuberculosis, to different intracellular vesicles.
  • the solid substrate may comprise magnetic beads or other structured materials, which then pull microbes out from fluids, including biological fluids such as blood, and concentrate and collect the microbes, including living microbes.
  • fluids including biological fluids such as blood
  • the engineered opsonin may be used in diagnostics as a means of collecting potential pathogens for identification; not only in the diagnosis of disease, but in the identification of water- or food-borne pathogens, particulates or other contaminants.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Botany (AREA)
PCT/US2011/021603 2010-01-19 2011-01-19 Engineered opsonin for pathogen detection and treatment Ceased WO2011090954A2 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
AU2011207626A AU2011207626B2 (en) 2010-01-19 2011-01-19 Engineered opsonin for pathogen detection and treatment
ES11735056.1T ES2678143T3 (es) 2010-01-19 2011-01-19 Opsonina obtenida por ingeniería genética para la detección y el tratamiento de microorganismos patógenos
JP2012550067A JP5959440B2 (ja) 2010-01-19 2011-01-19 病原体の検出および治療のための改変オプソニン
US13/574,191 US9150631B2 (en) 2010-01-19 2011-01-19 Engineered opsonin for pathogen detection and treatment
EP11735056.1A EP2526119B1 (en) 2010-01-19 2011-01-19 Engineered opsonin for pathogen detection and treatment
DK11735056.1T DK2526119T3 (en) 2010-01-19 2011-01-19 Manipulated opsonin for pathogen detection and treatment
CN201180014755.1A CN102947341B (zh) 2010-01-19 2011-01-19 用于病原体检测和治疗的工程化调理素
CA2787376A CA2787376A1 (en) 2010-01-19 2011-01-19 Engineered opsonin for pathogen detection and treatment
SG2012052965A SG182577A1 (en) 2010-01-19 2011-01-19 Engineered opsonin for pathogen detection and treatment
IN6589DEN2012 IN2012DN06589A (OSRAM) 2010-01-19 2011-01-19
US14/831,480 US20160200785A1 (en) 2010-01-19 2015-08-20 Engineered opsonin for pathogen detection and treatment
US15/839,352 US10538562B2 (en) 2010-01-19 2017-12-12 Engineered opsonin for pathogen detection and treatment
US16/702,724 US11059873B2 (en) 2010-01-19 2019-12-04 Engineered opsonin for pathogen detection and treatment
US16/892,577 US11059874B2 (en) 2010-01-19 2020-06-04 Engineered opsonin for pathogen detection and treatment
US16/892,575 US11203623B2 (en) 2010-01-19 2020-06-04 Engineered opsonin for pathogen detection and treatment
US17/522,115 US20220056089A1 (en) 2010-01-19 2021-11-09 Engineered opsonin for pathogen detection and treatment

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29622210P 2010-01-19 2010-01-19
US61/296,222 2010-01-19

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/574,191 A-371-Of-International US9150631B2 (en) 2010-01-19 2011-01-19 Engineered opsonin for pathogen detection and treatment
US14/831,480 Continuation US20160200785A1 (en) 2010-01-19 2015-08-20 Engineered opsonin for pathogen detection and treatment

Publications (2)

Publication Number Publication Date
WO2011090954A2 true WO2011090954A2 (en) 2011-07-28
WO2011090954A3 WO2011090954A3 (en) 2012-01-12

Family

ID=44307537

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/021603 Ceased WO2011090954A2 (en) 2010-01-19 2011-01-19 Engineered opsonin for pathogen detection and treatment

Country Status (11)

Country Link
US (7) US9150631B2 (OSRAM)
EP (1) EP2526119B1 (OSRAM)
JP (5) JP5959440B2 (OSRAM)
CN (1) CN102947341B (OSRAM)
AU (1) AU2011207626B2 (OSRAM)
CA (1) CA2787376A1 (OSRAM)
DK (1) DK2526119T3 (OSRAM)
ES (1) ES2678143T3 (OSRAM)
IN (1) IN2012DN06589A (OSRAM)
SG (2) SG182577A1 (OSRAM)
WO (1) WO2011090954A2 (OSRAM)

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012135034A1 (en) * 2011-03-25 2012-10-04 Receptors Llc Fiber with microbial removal, micro-biocidal, or static growth capability
WO2013012924A2 (en) 2011-07-18 2013-01-24 President And Fellows Of Harvard College Engineered microbe-targeting molecules and uses thereof
WO2013130875A1 (en) * 2012-02-29 2013-09-06 President And Fellows Of Harvard College Rapid antibiotic susceptibility testing
WO2014014788A3 (en) * 2012-07-18 2014-03-13 President And Fellows Of Harvard College Modification of surfaces for simulataneous repellency and targeted binding of desired moieties
US20140220617A1 (en) * 2011-04-01 2014-08-07 Children's Medical Center Corporation Dialysis like therapeutic (dlt) device
WO2014144325A1 (en) 2013-03-15 2014-09-18 President And Fellows Of Harvard College Methods and compositions for improving detection and/or capture of a target entity
WO2014190040A1 (en) 2013-05-21 2014-11-27 President And Fellows Of Harvard College Engineered heme-binding compositions and uses thereof
WO2015009734A2 (en) 2013-07-15 2015-01-22 President And Fellows Of Harvard College Assays for antimicrobial activity and applications thereof
US9150631B2 (en) 2010-01-19 2015-10-06 President And Fellows Of Harvard College Engineered opsonin for pathogen detection and treatment
DE102014206444A1 (de) * 2014-04-03 2015-10-08 Siemens Aktiengesellschaft Verfahren für die Molekulardiagnostik zum Anreichern einer Nukleinsäure aus einer biologischen Probe
US9156037B2 (en) 2009-01-15 2015-10-13 Children's Medical Center Corporation Microfluidic device and uses thereof
US9220831B2 (en) 2005-10-06 2015-12-29 Children's Medical Center Corporation Device and method for combined microfluidic-micromagnetic separation of material in continuous flow
WO2017024114A1 (en) 2015-08-06 2017-02-09 President And Fellows Of Harvard College Improved microbe-binding molecules and uses thereof
WO2017201064A1 (en) 2016-05-16 2017-11-23 President And Fellows Of Harvard College Aqueous biomolecule coupling on co2-plasma-activated surfaces
US10357780B2 (en) 2014-10-27 2019-07-23 President And Fellows Of Harvard College Magnetic capture of a target from a fluid
EP3546474A2 (en) 2013-12-18 2019-10-02 President and Fellows of Harvard College Crp capture/detection of gram positive bacteria
WO2021133963A1 (en) 2019-12-23 2021-07-01 Miraki Innovation Think Tank Llc Sample preparation and microbial analysis
WO2021133943A1 (en) 2019-12-23 2021-07-01 Miraki Innovation Think Tank Llc Compositions, devices and methods for diagnosing and treating infectious disease
WO2021252902A1 (en) 2020-06-12 2021-12-16 Miraki Innovation Think Tank Llc Lateral flow assay for rapid detection of pathogens in samples
WO2022026800A2 (en) 2020-07-31 2022-02-03 Miraki Innovation Think Tank Llc Mbl-coated substrates having anti-thrombogenic properties
WO2022046558A1 (en) 2020-08-28 2022-03-03 Miraki Innovation Think Tank Llc Therapeutic compositions comprising microbe-targeting molecules and their use in methods of preventing and treating infectious disease
WO2022067006A1 (en) 2020-09-25 2022-03-31 Miraki Innovation Think Tank Llc Compositions, devices and methods comprising microbe-targeting molecules for diagnosing and treating infectious disease
WO2022072674A1 (en) 2020-10-01 2022-04-07 Miraki Innovation Think Tank Llc Compositions, devices and methods for identifying, treating and preventing infectious disease using microbe-targeting molecules
WO2022093935A1 (en) 2020-10-27 2022-05-05 Miraki Innovation Think Tank Llc Compositions, systems and methods for pathogen monitoring using microbe-targeting molecules
WO2022125632A1 (en) 2020-12-08 2022-06-16 Miraki Innovation Think Tank Llc Chimeric antigen receptor-expressing cells targeting microbe-associated molecular patterns

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2632630C (en) 2005-12-13 2016-12-06 President And Fellows Of Harvard College Scaffolds for cell transplantation
US10328133B2 (en) 2008-02-13 2019-06-25 President And Fellows Of Harvard College Continuous cell programming devices
ES2773858T3 (es) 2010-10-06 2020-07-15 Harvard College Hidrogeles formadores de poros inyectables para terapias celulares basadas en materiales
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
CN104244929B (zh) 2012-04-16 2017-04-05 哈佛学院董事会 用于调节免疫反应的介孔二氧化硅组合物
US20130334120A1 (en) * 2012-06-15 2013-12-19 President And Fellows Of Harvard College Fluid cleansing devices and methods of use
CN107073090A (zh) 2014-04-30 2017-08-18 哈佛学院董事会 结合的疫苗装置和杀死癌细胞的方法
EP3250250A4 (en) 2015-01-30 2019-05-22 President and Fellows of Harvard College PERITUMORAL AND INTRATUMORAL MATERIALS FOR CANCER THERAPY
CN114099793A (zh) 2015-04-10 2022-03-01 哈佛学院院长等 免疫细胞捕获装置及其制备和使用方法
ES2909116T3 (es) 2015-09-14 2022-05-05 Medisieve Ltd Aparato de filtro magnético
CN115487351A (zh) 2016-02-06 2022-12-20 哈佛学院校长同事会 重塑造血巢以重建免疫
US10813988B2 (en) * 2016-02-16 2020-10-27 President And Fellows Of Harvard College Pathogen vaccines and methods of producing and using the same
CA3030427A1 (en) 2016-07-13 2018-01-18 President And Fellows Of Harvard College Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
BR112019000748A2 (pt) 2016-07-28 2019-04-24 Medisieve Ltd método e misturador magnético
JP7274214B2 (ja) 2016-08-02 2023-05-16 プレジデント アンド フェローズ オブ ハーバード カレッジ 免疫応答を調節するための生体材料
WO2019064463A1 (ja) * 2017-09-28 2019-04-04 学校法人中部大学 バイオアフィニティーを利用したウイルス又は細菌の濃縮方法及び装置
KR102084688B1 (ko) * 2018-06-18 2020-03-04 울산과학기술원 다중 프로브 혼성화를 이용한 미생물 검출 방법
WO2020061129A1 (en) 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo
CN110628624B (zh) * 2019-02-01 2022-07-15 传鸣(宁波)化学科技有限公司 一种磁性微生物捕获材料及微生物捕获方法
CN110294810B (zh) * 2019-06-26 2021-05-04 中国疾病预防控制中心传染病预防控制所 一种含有人IgG1Fc和甘露聚糖结合凝集素C端的重组蛋白
US12194157B2 (en) 2020-04-09 2025-01-14 Finncure Oy Carrier for targeted delivery to a host
WO2021205077A1 (en) 2020-04-09 2021-10-14 Finncure Oy Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses
US12390548B2 (en) 2020-05-14 2025-08-19 Mehrdad Michael HOGHOOGHI System and method for protecting a workspace from airborne contaminants
CN111675825B (zh) * 2020-06-09 2022-06-24 大连工业大学 一种附有胰蛋白酶的微孔膜的制备方法及其在蛋白水解中的应用
WO2022151333A1 (zh) * 2021-01-15 2022-07-21 传鸣(宁波)化学科技有限公司 用于富集微生物的混合物、方法及应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
WO2003054164A2 (en) 2001-12-19 2003-07-03 Immunex Corporation C-type lectin polypeptide, polynucleotide and methods of making and use thereof
WO2004018698A2 (en) 2002-08-20 2004-03-04 Genitrix, Llc Lectin compositions and methods for modulating an immune response to an antigen
US20080193965A1 (en) 2006-10-10 2008-08-14 Oakland University Microorganism detection and analysis using carbohydrate and lectin recognition
WO2009062195A2 (en) 2007-11-09 2009-05-14 Anaphore, Inc. Fusion proteins of mannose binding lectins for treatment of disease
WO2009126346A2 (en) 2008-01-18 2009-10-15 The General Hospital Corporation Methods for prevention and treatment of infections with supraphysiological doses of mannan-binding lectin (mbl) and ficolin-mbl fusion proteins

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5418198A (en) 1977-07-09 1979-02-09 Toshimitsu Niwa Artificial intraretinal device
US4425330A (en) 1981-05-20 1984-01-10 Cornell Research Foundation, Inc. Bovine mastitis vaccine and method for detecting efficacy thereof
JPS60500548A (ja) 1982-12-03 1985-04-18 イ−・アイ・デユポン・ド・ネモア−ス・アンド・コンパニ− 発色性支持体免疫測定法
EP0126772A1 (en) 1982-12-03 1984-12-05 E.I. Du Pont De Nemours And Company Chromogenic support immunoassay
JPH0718875B2 (ja) 1987-06-19 1995-03-06 ヤマサ醤油株式会社 血中または体液中の微量物質含有量の測定法
US5270199A (en) 1987-08-20 1993-12-14 The Children's Medical Center Corporation Human mannose-binding protein
EP0375736B1 (en) 1987-08-20 1998-05-13 Children's Medical Center Corporation Nucleic acid fragments encoding mannose binding fragments of human mannose binding protein
ATE122568T1 (de) 1989-01-25 1995-06-15 Commw Scient Ind Res Org Polypeptide, antigene oder vakzine gegen babesiosis.
US5137810A (en) * 1989-04-26 1992-08-11 The University Of North Carolina Method of determining the gram sign of bacteria
DE4018583A1 (de) 1990-06-09 1991-12-12 Henkel Kgaa Modifiziertes verfahren zur direkten herstellung von alkylglykosiden
DK0542833T3 (da) 1990-07-30 2000-03-27 Novartis Ag Insekticide proteiner
GB9020075D0 (en) 1990-09-14 1990-10-24 Filler Aaron G Contrast agents for magnetic resonance imaging of axonal transport
JPH04130274A (ja) 1990-09-20 1992-05-01 Kyoto Ikagaku Kenkyusho:Kk 糖蛋白の分析，検出方法
US5783179A (en) 1991-08-09 1998-07-21 Syntex (U.S.A.) Inc. C-reactive protein fragment with immunomodulatory activity
US5874238A (en) 1993-02-26 1999-02-23 Immtech International Inc. Mutant protein and methods and materials for making and using it
US5405832A (en) 1991-11-27 1995-04-11 Immtech International Inc. Method of treating non-streptococcal bacterial infections
EP0616535B1 (en) 1991-11-27 2000-02-02 Immtech International Incorporated Method of treating viral infections
US5283238A (en) 1992-04-24 1994-02-01 Immtech International, Inc. Methods of treating cancer using modified C-reactive protein
US6703219B1 (en) 1993-02-26 2004-03-09 Immtech International Inc. Mutant protein and methods and materials for making and using it
IT1271486B (it) 1993-10-12 1997-05-28 Italfarmaco Spa Oligopeptidi immunomodulatori derivati di frammenti della proteina c- reattiva
AUPN214095A0 (en) * 1995-04-03 1995-04-27 Australian Water Technologies Pty Ltd Method for detecting microorganisms using flow cytometry
WO1997035619A1 (en) 1996-03-28 1997-10-02 Genitrix, L.L.C. Opsonin-enhanced cells, and methods of modulating an immune response to an antigen
ZA973051B (en) 1996-04-24 1998-10-12 Genentech Inc Type c lectins
US6117977A (en) 1996-04-24 2000-09-12 Genentech, Inc. Type C lectins
FR2751229B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins
US6294170B1 (en) * 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
IL121191A0 (en) 1997-06-29 1997-11-20 Yeda Res & Dev Synthetic peptides and pharmaceutical compositions comprising them
JPH11206378A (ja) 1998-01-23 1999-08-03 Fuso Pharmaceutical Industries Ltd 組換えヒトマンナン結合タンパク質およびその製造方法
US7049099B2 (en) 1998-01-23 2006-05-23 Fuso Pharmaceutical Industries, Ltd. Recombinant human mannan-binding proteins and producing method of the same
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
JP4707231B2 (ja) 1998-06-10 2011-06-22 スタテンズ セーラム インスティテュート マンナン結合レクチンを製造するための精製方法及びｍｂｌ医薬品
JP5219057B2 (ja) 1998-07-31 2013-06-26 旭化成株式会社 微生物検出用抗体
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
RU2292217C2 (ru) 1999-05-14 2007-01-27 Стеффен ТИЭЛЬ Рекомбинантный маннан-связывающий лектин человека
ES2317843T3 (es) * 1999-07-13 2009-05-01 Bolder Biotechnology, Inc. Proteinas de fusion de eritropoyetina-inmunoglobulina.
US6503761B1 (en) 1999-10-19 2003-01-07 Kimberly-Clark Worldwide, Inc. Selective removal of contaminants from a surface using articles having magnets
CN1406249B (zh) * 2000-02-11 2010-06-16 默克专利股份有限公司 增加基于抗体的融合蛋白的循环半衰期
US6471968B1 (en) 2000-05-12 2002-10-29 Regents Of The University Of Michigan Multifunctional nanodevice platform
JP2002165591A (ja) 2000-09-25 2002-06-11 Jsr Corp 磁性粒子およびその使用方法
AU2002227184A1 (en) 2000-10-18 2002-04-29 The Board Of Trustess Of The Leland Stanford Junior University Methods for development and use of diagnostic and therapeutic agents
GB0119274D0 (en) 2001-08-08 2001-10-03 Univ Durham Fusion proteins for insect control
US6900292B2 (en) * 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
EP1335003A3 (en) 2002-02-06 2004-04-07 Toyo Boseki Kabushiki Kaisha Magnetic carrier capable of binding with protein and purification method of protein utilizing the magnetic carrier
AU2003219730A1 (en) 2002-02-07 2003-09-02 Massachusetts Institute Of Technology Anti-pathogen treatements
WO2003077937A1 (en) 2002-03-15 2003-09-25 Natimmune A/S Pharmaceutical compositions comprising mannose binding lectin
US20030180814A1 (en) 2002-03-21 2003-09-25 Alastair Hodges Direct immunosensor assay
US7211396B2 (en) 2002-04-18 2007-05-01 Antibodyshop A/S Antibody pairs and kits for immunochemical determination of mannan-binding lectin
CA2483441A1 (en) 2002-04-24 2003-11-06 The Council Of The Queensland Institute Of Medical Research Mannose binding lectin and uses thereof
US20040018611A1 (en) 2002-07-23 2004-01-29 Ward Michael Dennis Microfluidic devices for high gradient magnetic separation
US7629440B2 (en) 2002-08-20 2009-12-08 Genitrix, Llc Lectin compositions and methods for modulating an immune response to an antigen
EP1539964B1 (en) 2002-09-10 2006-12-27 Natlmmune A/S Collectin-complement activating protein chimeras
GB2393728A (en) 2002-10-04 2004-04-07 Nanomagnetics Ltd Magnetic nanoparticles
EP1417965A1 (en) 2002-11-07 2004-05-12 Vereniging Voor Christelijk Wetenschappelijk Onderwijs C-type lectin binding molecules, identification and uses thereof
RU2353399C2 (ru) 2003-01-17 2009-04-27 Этлон Медикал, Инк. Способ удаления вирусов из крови посредством лектин-аффинного гемодиализа
US20050014932A1 (en) 2003-05-15 2005-01-20 Iogenetics, Llc Targeted biocides
DE10325752A1 (de) 2003-06-06 2004-12-30 Faustus Forschungs Cie. Translational Cancer Research Gmbh Lektin-Konjugate
WO2005040194A2 (en) 2003-10-24 2005-05-06 Ludwig Institute For Cancer Research Methods and compositions for pdgf-c activation and inhibition
KR20060124656A (ko) * 2003-12-31 2006-12-05 메르크 파텐트 게엠베하 개선된 약물동태를 가지는 Ｆｃ-에리스로포이에틴 융합단백질
EP2053062A1 (en) 2004-03-24 2009-04-29 Xencor, Inc. Immunoglobin variants outside the Fc region
SE0401033D0 (sv) 2004-04-20 2004-04-20 Amersham Biosciences Ab Device and method for protein analysis
US8080245B2 (en) 2004-08-04 2011-12-20 University Of Massachusetts Anti-pathogen immunoadhesins
US20090269843A1 (en) 2004-08-20 2009-10-29 Novo Nordisk A/S Hemopexin fusion proteins
EP1800136B1 (en) 2004-10-15 2011-12-07 Danisco US Inc. Competitive differential screening
DK1812459T3 (da) 2004-10-28 2011-05-23 Dobeel Co Ltd Fremgangsmåde til masseproduktion af multimer mannosebindende lectin
US20060141547A1 (en) 2004-11-16 2006-06-29 Das Hasi R Novel diagnostic marker, a diagnostic kit and a method for diagnosis of rheumatoid arthritis
US7172906B2 (en) 2004-11-16 2007-02-06 Dade Behring Inc. Reduction of non-specific binding in assays
US8084275B2 (en) 2005-02-08 2011-12-27 Fujifilm Corporation Magnetic composite body, production method thereof, method for removing substance with mannose on its surface, and method for concentrating substance with mannose on its surface
AU2006232310B9 (en) * 2005-04-06 2011-07-21 Ibc Pharmaceuticals, Inc. Improved stably tethered structures of defined compositions with multiple functions or binding specificities
CN101193651A (zh) 2005-04-11 2008-06-04 内蒂穆恩公司 甘露聚糖结合凝集素(mbl)在治疗与癌症相关的免疫削弱的病症中的用途
US20070031819A1 (en) 2005-04-26 2007-02-08 University Of Washington Microfluidic systems for biological and molecular analysis and methods thereof
EP2484344B1 (en) 2005-05-09 2016-02-10 Biosphere Medical, S.A. Compositions and methods of using microspheres and non-ionic contrast agents
US20070231833A1 (en) 2005-05-23 2007-10-04 Arcidiacono Steven M Labeled antimicrobial peptides and method of using the same to detect microorganisms of interest
JP4423394B2 (ja) * 2005-06-17 2010-03-03 独立行政法人産業技術総合研究所 新規糖鎖認識蛋白質及びその遺伝子
US20070072247A1 (en) 2005-08-31 2007-03-29 Academia Sinica Methods and reagents for the analysis and purification of polysaccharides
CN101273258A (zh) 2005-09-30 2008-09-24 卡钳生命科学股份有限公司 利用磁性珠纯化生物学组分的微流体装置
US9220831B2 (en) 2005-10-06 2015-12-29 Children's Medical Center Corporation Device and method for combined microfluidic-micromagnetic separation of material in continuous flow
US8013120B2 (en) 2005-10-26 2011-09-06 Stc.Unm C-reactive protein and its use to treat systemic lupus erythematosus and related conditions
WO2009148566A2 (en) 2008-06-03 2009-12-10 Stc.Unm Development of a c-reactive protein mutant with improved therapeutic benefit in immune thrombocytopenia and lupus nephritis
US20070269818A1 (en) 2005-12-28 2007-11-22 Affymetrix, Inc. Carbohydrate arrays
US20090181041A1 (en) 2006-01-23 2009-07-16 Jan Holgersson Production of proteins carrying oligomannose or human-like glycans in yeast and methods of use thereof
JP5063616B2 (ja) 2006-02-03 2012-10-31 インテジェニックス インコーポレイテッド マイクロ流体デバイス
US8821851B2 (en) 2006-03-23 2014-09-02 The General Hospital Corporation Inflammation-inhibitory serum factors and uses thereof
WO2007111496A1 (en) * 2006-03-28 2007-10-04 Universiteit Utrecht Holding B.V. Improved carbohydrate recognition domains
EP1862541A1 (en) 2006-06-01 2007-12-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Polypeptides derived from the hemopexin-like domain of metalloproteinase MMP-2
US8273310B2 (en) 2006-09-05 2012-09-25 Samsung Electronics Co., Ltd. Centrifugal force-based microfluidic device for nucleic acid extraction and microfluidic system including the microfluidic device
KR101343034B1 (ko) 2006-09-05 2013-12-18 삼성전자 주식회사 원심력 기반의 단백질 검출용 미세유동 장치 및 이를포함하는 미세유동 시스템
WO2009008925A2 (en) 2007-04-05 2009-01-15 The Regents Of The University Of California A particle-based microfluidic device for providing high magnetic field gradients
CA2682605A1 (en) 2007-04-18 2008-10-30 Zymogenetics, Inc. Single chain fc, methods of making and methods of treatment
US8292083B2 (en) 2007-04-19 2012-10-23 The Charles Stark Draper Laboratory, Inc. Method and apparatus for separating particles, cells, molecules and particulates
KR20100021601A (ko) 2007-05-14 2010-02-25 바이오겐 아이덱 엠에이 인코포레이티드 단일-쇄 Ｆｃ(ＳｃＦｃ) 부분, 이를 포함하는 결합 폴리펩타이드, 및 이에 관련된 방법
ES2415604T3 (es) 2007-05-30 2013-07-26 Postech Academy-Industry- Foundation Proteínas de fusión de inmunoglobulina
CA2704724A1 (en) 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag 5use of a peptide as a therapeutic agent
US8415118B2 (en) 2007-10-29 2013-04-09 Virginia Tech Intellectual Properties, Inc. Porcine DC-SIGN, ICAM-3 and LSECtin and uses thereof
ES2326109B1 (es) 2007-12-05 2010-06-25 Consejo Superior De Investigaciones Cientificas Microdispositivo de separacion y extraccion selectiva y no invasiva de particulas en suspensiones polidispersas, procedimiento de fabricacion y sus aplicaciones.
US20100266558A1 (en) 2007-12-18 2010-10-21 Dov Zipori Method and assay for glycosylation pattern detection related to cell state of stem cells
CN101952727A (zh) 2007-12-31 2011-01-19 3M创新有限公司 微生物捕获用组合物和方法
KR101625979B1 (ko) 2008-03-28 2016-05-31 국립대학법인 홋가이도 다이가쿠 항 ｈ5 아형 ａ형 인플루엔자 바이러스 헤마글루티닌 모노클로날 항체
US20110053145A1 (en) 2008-03-31 2011-03-03 Japan Tobacco Inc. Quantitation method of virus
AU2009232598A1 (en) 2008-03-31 2009-10-08 Japan Tobacco Inc. Enrichment method of virus
US20100323429A1 (en) 2008-04-10 2010-12-23 Yu-Chen Hu Methods for purifying baculovirus
US8865876B2 (en) 2008-06-02 2014-10-21 California Institute Of Technology Engineered lectin oligomers with antiviral activity
JP2010122205A (ja) 2008-08-29 2010-06-03 Sysmex Corp 麻疹ウイルス検出方法、メンブレンアッセイ用試験具およびメンブレンアッセイ用試験キット
WO2010028306A2 (en) 2008-09-05 2010-03-11 The Regents Of The University Of California Office Of The President Antibodies with mannose binding lectin effector function for inhibiting pathologic inflammatory conditions
WO2010065765A2 (en) 2008-12-04 2010-06-10 Aethlon Medical, Inc. Affinity capture of circulating biomarkers
ES2536198T3 (es) 2008-12-22 2015-05-21 National University Corporation Hokkaido University Sustancia proteínica que tiene estructura de hélice triple y método de producción de la misma
WO2010078966A1 (en) * 2009-01-09 2010-07-15 Apogenix Gmbh Fusion proteins forming trimers
CA2750533A1 (en) 2009-01-23 2010-07-29 Biogen Idec Ma Inc. Stabilized fc polypeptides with reduced effector function and methods of use
JP2012516338A (ja) 2009-01-28 2012-07-19 スマートセルズ・インコーポレイテツド 結合部位が修飾されたレクチンおよびその使用
US20130012451A1 (en) 2009-12-21 2013-01-10 The Research Foundation Of State University Of New York Compositions and methods for inhibiting mmp-9-mediated cell migration
US20130157283A1 (en) 2010-01-19 2013-06-20 President And Fellows Of Harvard College Rapid pathogen diagnostic device and method
DK2526119T3 (en) 2010-01-19 2018-07-30 Harvard College Manipulated opsonin for pathogen detection and treatment
JP6228012B2 (ja) 2011-01-19 2017-11-08 プレジデント アンド フェローズ オブ ハーバード カレッジ 高圧力安定性、光透過性、および自己修復特性を伴う易滑性表面
RU2013148071A (ru) 2011-04-01 2015-05-10 Президент Энд Феллоуз Ов Харвард Колледж Аналогичное диализу терапевтическое (dlt) устройство
US9593160B2 (en) 2011-07-18 2017-03-14 President And Fellows Of Harvard College Engineered microbe-targeting molecules and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
WO2003054164A2 (en) 2001-12-19 2003-07-03 Immunex Corporation C-type lectin polypeptide, polynucleotide and methods of making and use thereof
WO2004018698A2 (en) 2002-08-20 2004-03-04 Genitrix, Llc Lectin compositions and methods for modulating an immune response to an antigen
US20080193965A1 (en) 2006-10-10 2008-08-14 Oakland University Microorganism detection and analysis using carbohydrate and lectin recognition
WO2009062195A2 (en) 2007-11-09 2009-05-14 Anaphore, Inc. Fusion proteins of mannose binding lectins for treatment of disease
WO2009126346A2 (en) 2008-01-18 2009-10-15 The General Hospital Corporation Methods for prevention and treatment of infections with supraphysiological doses of mannan-binding lectin (mbl) and ficolin-mbl fusion proteins

Cited By (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9220831B2 (en) 2005-10-06 2015-12-29 Children's Medical Center Corporation Device and method for combined microfluidic-micromagnetic separation of material in continuous flow
US9156037B2 (en) 2009-01-15 2015-10-13 Children's Medical Center Corporation Microfluidic device and uses thereof
US11203623B2 (en) 2010-01-19 2021-12-21 President And Fellows Of Harvard College Engineered opsonin for pathogen detection and treatment
US10538562B2 (en) 2010-01-19 2020-01-21 President And Fellows Of Harvard College Engineered opsonin for pathogen detection and treatment
US11059874B2 (en) 2010-01-19 2021-07-13 President And Fellows Of Harvard College Engineered opsonin for pathogen detection and treatment
US11059873B2 (en) 2010-01-19 2021-07-13 President And Fellows Of Harvard College Engineered opsonin for pathogen detection and treatment
US9150631B2 (en) 2010-01-19 2015-10-06 President And Fellows Of Harvard College Engineered opsonin for pathogen detection and treatment
WO2012135042A1 (en) * 2011-03-25 2012-10-04 Receptors Llc Filtration article with microbial removal, micro-biocidal, or static growth capability
WO2012135034A1 (en) * 2011-03-25 2012-10-04 Receptors Llc Fiber with microbial removal, micro-biocidal, or static growth capability
GB2502927A (en) * 2011-03-25 2013-12-11 Receptors Llc Fiber with microbial removal, micro-biocidal, or static growth capability
US20140220617A1 (en) * 2011-04-01 2014-08-07 Children's Medical Center Corporation Dialysis like therapeutic (dlt) device
US9593160B2 (en) 2011-07-18 2017-03-14 President And Fellows Of Harvard College Engineered microbe-targeting molecules and uses thereof
WO2013012924A2 (en) 2011-07-18 2013-01-24 President And Fellows Of Harvard College Engineered microbe-targeting molecules and uses thereof
US11795212B2 (en) 2011-07-18 2023-10-24 President And Fellows Of Harvard College Engineered microbe-targeting molecules and uses thereof
US10526399B2 (en) 2011-07-18 2020-01-07 President And Fellows Of Harvard College Engineered microbe-targeting molecules and uses thereof
AU2017254907B2 (en) * 2011-07-18 2019-08-15 President And Fellows Of Harvard College Engineered microbe-targeting molecules and uses thereof
WO2013012924A3 (en) * 2011-07-18 2013-04-11 President And Fellows Of Harvard College Engineered microbe-targeting molecules and uses thereof
US10865235B2 (en) 2011-07-18 2020-12-15 President And Fellows Of Harvard College Engineered microbe-targeting molecules and uses thereof
EP3081937A1 (en) 2011-07-18 2016-10-19 President and Fellows of Harvard College Engineered microbe-targeting molecules and uses thereof
WO2013130875A1 (en) * 2012-02-29 2013-09-06 President And Fellows Of Harvard College Rapid antibiotic susceptibility testing
CN104284984A (zh) * 2012-02-29 2015-01-14 哈佛大学校长及研究员协会 抗生素药敏性的快速测试
US9632085B2 (en) 2012-02-29 2017-04-25 President And Fellows Of Harvard College Rapid antibiotic susceptibility testing
EP2820147A4 (en) * 2012-02-29 2015-10-14 Harvard College FAST TESTS FOR SENSITIVITY AGAINST ANTIBIOTICS
EP2820147B1 (en) * 2012-02-29 2018-08-08 President and Fellows of Harvard College Rapid antibiotic susceptibility testing
US20150064703A1 (en) * 2012-02-29 2015-03-05 President And Fellows Of Harvard College Rapid antibiotic susceptibility testing
WO2014014788A3 (en) * 2012-07-18 2014-03-13 President And Fellows Of Harvard College Modification of surfaces for simulataneous repellency and targeted binding of desired moieties
US10551379B2 (en) 2013-03-15 2020-02-04 President And Fellows Of Harvard College Methods and compositions for improving detection and/or capture of a target entity
WO2014144325A1 (en) 2013-03-15 2014-09-18 President And Fellows Of Harvard College Methods and compositions for improving detection and/or capture of a target entity
US10501729B2 (en) 2013-05-21 2019-12-10 President And Fellows Of Harvard College Engineered heme-binding compositions and uses thereof
EP3848044A1 (en) 2013-05-21 2021-07-14 President and Fellows of Harvard College Engineered heme-binding compositions and uses thereof
US11939608B2 (en) 2013-05-21 2024-03-26 President And Fellows Of Harvard College Engineered heme-binding compositions and uses thereof
WO2014190040A1 (en) 2013-05-21 2014-11-27 President And Fellows Of Harvard College Engineered heme-binding compositions and uses thereof
US11312949B2 (en) 2013-05-21 2022-04-26 President And Fellows Of Harvard College Engineered heme-binding compositions and uses thereof
EP3848045A1 (en) 2013-05-21 2021-07-14 President and Fellows of Harvard College Engineered heme-binding compositions and uses thereof
EP3748010A1 (en) 2013-07-15 2020-12-09 President and Fellows of Harvard College Assays for antimicrobial activity and applications thereof
WO2015009734A2 (en) 2013-07-15 2015-01-22 President And Fellows Of Harvard College Assays for antimicrobial activity and applications thereof
EP3521442A1 (en) 2013-07-15 2019-08-07 President and Fellows of Harvard College Assays for antimicrobial activity and applications thereof
US10718766B2 (en) 2013-07-15 2020-07-21 President And Fellows Of Harvard College Assays for antimicrobial activity and applications thereof
US11209432B2 (en) 2013-07-15 2021-12-28 President And Fellows Of Harvard College Assays for antimicrobial activity and applications thereof
US9791440B2 (en) 2013-07-15 2017-10-17 President And Fellows Of Harvard College Assays for antimicrobial activity and applications thereof
US10513546B2 (en) 2013-12-18 2019-12-24 President And Fellows Of Harvard College CRP capture/detection of gram positive bacteria
US11718651B2 (en) 2013-12-18 2023-08-08 President And Fellows Of Harvard College CRP capture/detection of gram positive bacteria
US11034744B2 (en) 2013-12-18 2021-06-15 President And Fellows Of Harvard College CRP capture/detection of gram positive bacteria
EP3546474A2 (en) 2013-12-18 2019-10-02 President and Fellows of Harvard College Crp capture/detection of gram positive bacteria
EP3912986A2 (en) 2013-12-18 2021-11-24 President and Fellows of Harvard College Crp capture/detection of bacteria
DE102014206444A1 (de) * 2014-04-03 2015-10-08 Siemens Aktiengesellschaft Verfahren für die Molekulardiagnostik zum Anreichern einer Nukleinsäure aus einer biologischen Probe
US10357780B2 (en) 2014-10-27 2019-07-23 President And Fellows Of Harvard College Magnetic capture of a target from a fluid
US11059050B2 (en) 2014-10-27 2021-07-13 President And Fellows Of Harvard College Magnetic capture of a target from a fluid
US11236149B2 (en) 2015-08-06 2022-02-01 President And Fallows Of Harvard College Microbe-binding molecules and uses thereof
US10435457B2 (en) 2015-08-06 2019-10-08 President And Fellows Of Harvard College Microbe-binding molecules and uses thereof
US11807677B2 (en) 2015-08-06 2023-11-07 President And Fellows Of Harvard College Microbe-binding molecules and uses thereof
EP3763378A1 (en) 2015-08-06 2021-01-13 President and Fellows of Harvard College Improved microbe-binding molecules and uses thereof
WO2017024114A1 (en) 2015-08-06 2017-02-09 President And Fellows Of Harvard College Improved microbe-binding molecules and uses thereof
US10696733B2 (en) 2015-08-06 2020-06-30 President And Fellows Of Harvard College Microbe-binding molecules and uses thereof
CN108289928A (zh) * 2015-08-06 2018-07-17 哈佛大学校长及研究员协会 改进的微生物-结合分子和其用途
WO2017201064A1 (en) 2016-05-16 2017-11-23 President And Fellows Of Harvard College Aqueous biomolecule coupling on co2-plasma-activated surfaces
US11919971B2 (en) 2016-05-16 2024-03-05 President And Fellows Of Harvard College Aqueous biomolecule coupling on CO2-plasma-activated surfaces
WO2021133943A1 (en) 2019-12-23 2021-07-01 Miraki Innovation Think Tank Llc Compositions, devices and methods for diagnosing and treating infectious disease
WO2021133963A1 (en) 2019-12-23 2021-07-01 Miraki Innovation Think Tank Llc Sample preparation and microbial analysis
WO2021252902A1 (en) 2020-06-12 2021-12-16 Miraki Innovation Think Tank Llc Lateral flow assay for rapid detection of pathogens in samples
WO2022026800A3 (en) * 2020-07-31 2022-03-03 Miraki Innovation Think Tank Llc Mbl-coated substrates having anti-thrombogenic properties
WO2022026800A2 (en) 2020-07-31 2022-02-03 Miraki Innovation Think Tank Llc Mbl-coated substrates having anti-thrombogenic properties
WO2022046558A1 (en) 2020-08-28 2022-03-03 Miraki Innovation Think Tank Llc Therapeutic compositions comprising microbe-targeting molecules and their use in methods of preventing and treating infectious disease
WO2022067006A1 (en) 2020-09-25 2022-03-31 Miraki Innovation Think Tank Llc Compositions, devices and methods comprising microbe-targeting molecules for diagnosing and treating infectious disease
WO2022072674A1 (en) 2020-10-01 2022-04-07 Miraki Innovation Think Tank Llc Compositions, devices and methods for identifying, treating and preventing infectious disease using microbe-targeting molecules
WO2022093935A1 (en) 2020-10-27 2022-05-05 Miraki Innovation Think Tank Llc Compositions, systems and methods for pathogen monitoring using microbe-targeting molecules
WO2022125632A1 (en) 2020-12-08 2022-06-16 Miraki Innovation Think Tank Llc Chimeric antigen receptor-expressing cells targeting microbe-associated molecular patterns

Also Published As

Publication number Publication date
WO2011090954A3 (en) 2012-01-12
IN2012DN06589A (OSRAM) 2015-10-23
AU2011207626A2 (en) 2012-10-04
CN102947341B (zh) 2018-07-06
AU2011207626B2 (en) 2015-06-18
JP2013517327A (ja) 2013-05-16
US20200291083A1 (en) 2020-09-17
JP2020193201A (ja) 2020-12-03
US20220056089A1 (en) 2022-02-24
JP7062723B2 (ja) 2022-05-06
US11059873B2 (en) 2021-07-13
US11203623B2 (en) 2021-12-21
JP2022097536A (ja) 2022-06-30
ES2678143T3 (es) 2018-08-09
US9150631B2 (en) 2015-10-06
CA2787376A1 (en) 2011-07-28
JP5959440B2 (ja) 2016-08-02
US20130035283A1 (en) 2013-02-07
US11059874B2 (en) 2021-07-13
EP2526119B1 (en) 2018-05-30
SG10201503351RA (en) 2015-06-29
US20180094035A1 (en) 2018-04-05
CN102947341A (zh) 2013-02-27
EP2526119A4 (en) 2013-10-02
JP6960957B2 (ja) 2021-11-05
JP6513604B2 (ja) 2019-05-15
US10538562B2 (en) 2020-01-21
JP2017014194A (ja) 2017-01-19
EP2526119A2 (en) 2012-11-28
US20200095300A1 (en) 2020-03-26
SG182577A1 (en) 2012-08-30
AU2011207626A1 (en) 2012-08-09
DK2526119T3 (en) 2018-07-30
US20200299345A1 (en) 2020-09-24
JP2019142901A (ja) 2019-08-29
US20160200785A1 (en) 2016-07-14

Similar Documents

Publication Publication Date Title
US11203623B2 (en) Engineered opsonin for pathogen detection and treatment
Foster The MSCRAMM family of cell-wall-anchored surface proteins of gram-positive cocci
Pietrocola et al. Streptococcus agalactiae non-pilus, cell wall-anchored proteins: involvement in colonization and pathogenesis and potential as vaccine candidates
CA2633345C (en) A method of affinity separation and ligands for use therein
Frick et al. Protein H‐‐a bacterial surface protein with affinity for both immunoglobulin and fibronectin type III domains.
EP0411017B1 (en) Binding of immune complexes by modified forms of c-reactive protein
Ghebrehiwet et al. gC1q-R/p33: structure-function predictions from the crystal structure
JP2000513949A (ja) 生物学的サンプル中における生物学的分子の検出のためのバクテリオファージの使用に基づく方法
HK1178914B (en) Engineered opsonin for pathogen detection and treatment
HK1178914A (en) Engineered opsonin for pathogen detection and treatment
Bezdekova et al. From Natural to Artificial Biorecognition Elements: From Antibodies to Molecularly Imprinted Polymers
Bezdekova et al. Imprinted Polymers
Thompson et al. Acoustic wave study of interfacially-bound proteins, nucleic acids and blood platelets
Morgan et al. Structure–Function Relationships in CD59
Morgan et al. 11 Structure–Function Relationships in CD59
JP2007509606A5 (OSRAM)

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180014755.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11735056

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2787376

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2012550067

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011207626

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 6589/DELNP/2012

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2011735056

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2011207626

Country of ref document: AU

Date of ref document: 20110119

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13574191

Country of ref document: US